An ual , epott Year ended 31 March 2022 Yorkshire Cancer. Research CONTENTS Welcome: Introduction to our charity Chief Executlve's Welcome 03 Chair's Report 05 Trustees and Strategic Report Our Team- Board of Trustees 07 Our Purpose Our Vision and Values 09 Strategic Aims Our Key Achievement5 - Our research in numbers Working to prevent cancer Diagnosing cancer early Improving cancer treatments - Other charity achievement5 io 12 16 20 24 Flnancial Review - General Financial Review and Principle Sources of Funding 28 Principal Risks and Uncertainties Independent Auditors Report 36 Con501idated Financlal Statements Financial Statements 40 Balance Sheet 42 Notes to financial statements Yorkshire's independent cancercharity. Yorkshire 15 one of the region5 hardest hit by cancer. Yorkshire Cancer Research exists to change this. More people are diagnosed with this lrfe-changing disease in our region than In most other parts of England. More people Suffer the tragedy of losing a loved one. Yorkshire Cancer Research exists to reduce these health inequalities and save lives. By bringing cancer research to Yorkshire. we shine a spotlight on the region s biggest cancer problems and attract the very best cancer experts from around the country and the world. Together, we are finding new and better ways to help save more lives - in your city, your town and your local community. Yorkshire Cancer. Research For every family who's lost a loved one For the people who still don't know they're at risk For the cures we haven't found yet For world-class treatment no matter who you are, or where you live For North, South. East and West Yorkshire For this generation For the next generation For more life without canor ? CHIEF EXECUTIVE'S I￿￿1￿111 WELCOME Hello, l am delightedto lntru(*xeYLYkthweCartsrRwr(hSknM￿ Rwrt fuThYrai5ersand kn31 Comm[￿1tygr*XpS-￿itl￿tal of these PEc**p￿r￿aY tK*teaiYetocarry outourvitd rde Thar￿￿ElL very L*stand L*&treatmentsforc3nw. Thsyww* aWar(l￿£11.7mlolUTrd repre*nt&J.'LÉvdliwvJ ￿rnaYbe a r￿p￿￿fry9￿￿etMJt itswth* ojr ttw1tythtr￿en￿rO tO￿ard5s1r￿I92S.erwriro tw kEalthr￿U￿rtie5arer￿dlKedwmIStar￿￿dSofC￿e iffycv&l. ThisyearwewroteanoFen ￿er to th￿ Health Secretary. SajKI ￿(￿r￿j UpY￿ hintostaTrJ tyhlscommttmerrtto p￿L￿dea￿*1￿0nal￿md￿foru￿CaIKer￿r(I￿￿pr£*￿DTh*. We ntributed to Drj￿ed Khan08Vs'M*ryJg)¥￿NJ(￿￿4ete.1￿rtt nati(rral rnedk4 attentmwe ￿aLSO pwbopoted in TheCBrr£rVoiTr'urgiryJ ￿*￿￿emMentto this￿. benefit- an athantajefelt byEwewne. Re*archfurKfro attr￿5 reSe*C￿*¥I repre*nts neaty8%oftheLIKs txrtcty3% ￿M8￿c81 re5￿ChfU￿1￿1J.￿eYPjttt0 o*roe thig Thsye¥wear4 agaryttEby>stfurNJerofcar£er TesearthstttytyFkn￿York5hiTe- We thankS￿fOry(XIT￿lnfWbthr#jWt atoJtoJrth*ttyaThJ u5aThJ save IntesinYorksFire. S￿￿erely. Dr. K2thryn ￿Ott d yorkshirecunc4rreseor¢h.org.uk CHAIR'S REPORT Welcome, l am priwleged tobwlccffie ￿ tottysfv AnNal Rew YorksFireCanw Research is an i￿epe1¥jentChartyth8t tro5avrt4 role ints* Iwlthof oJrregiorL our rArtkA)k goes far beyorxlyorkshire. ￿rairn ￿tOgNe pa¥le inyorkslire atce55to the best and latest cancer treatrnentsfrom arouTrl the to plOr￿ rwi iM￿at1)n5 Inca￿er cwe . whichthen goon to improve carw acr0551hegki Thisyearwe laU￿d a aryj imwrtwrt Irfi￿ent in Car￿ exwcise reha￿l[tatI¢￿. Partn2rirKJ with Sheffield HalIam'sA(fvar￿ed Wel￿e1￿ Re5earchCentre. pw)1eb￿thC3ncersrÈ beirvJ offered an iThYNidualwl prwamrne0fexerc￿e. aTvJ nu1rtll￿ gJPFQrt. New research ftom acro55the world indicates tW exerctse. in t￿)ju[￿tionwith tradittt)￿ forn￿ of caKer treatrnent 1gJrgery, chemotheraFY and radh)theraFwX can 5V4nifKanttyimpr￿eCa￿gjNlvaI rate5 a trartsform INe& We are exctted by this opFKJrtunty at•J aim to be * theforefrirt of exerose c¥)colwso that evewe with cancer inyoththtye Can￿1￿￿￿tfrOrn this. We k))k forward to sharing ne*s of otlEr gjch prL¥rame5 in the com1r9￿aT. Thereare I30.0￿ peopge in York5hirE FAArtripatinJ n rese￿Ch fuThknJ by(yJdwtty. We FEve 54 active re5eaTch awards aTrY 756 researc1￿$. cantywJertsandcAncerthampiws across the Countrya￿W(xkIngon programmes funded tyyorkshwe CatKer Researckn hdpiTYJ tofind solution5toYorkslwre's blggest carKer Proble￿￿. are thathl to ewor*of these irKlwhlu* for hdpng tochar¥Je Yorkshire's c￿[ sicry. forg¢xxJ. FolkY￿1r￿J th2dL%ruptK￿ caused bythe paThJemi l am pleaEed toreiMYtth3t cwr research programmes are runnirKJ at full capKity. Try5 sakl. we nMstwJ￿aCkMkdgethatthetc￿l on people with canw has been greatandthe impart oftfrt paThJemKwill contiryje to be fert for years tocorne. make5 useven rTh)redetemiir*d to attr￿tthe supiKrt aTrY fu￿ling to ilwestin n&v to help rEoplewfth aThJ efi9j￿ that p￿*are a￿e tofNe k￿j￿d healtlry Iwe5. Bestwthes. Graham BeNlle Trustees Report Yorkshire Cancer Researcli 6 yorkshlrecanc¢fftseqrclLorg.uk BOARD OF TRUSTEES EXECUTIVE TEAM Mr Graham 8erville BSC (Hons) (Chair) Dr Kathwh Scott Bso PhD Chief Executwe Mrs Sandra Dodson BA (Hon¥ (OepLtty Chair) Dr Yvette Oade Bsc (Honsl. MBChB. FRCPCH Mfs Juliet Glendinning BA (Hons). Dip Director of Bfand Relationships Mrs Joanne Mornin BA (Hons). ACA Difector of FInar￿ and Corporate 5ervice5. Company Secretary (appointed 01 Jan 20211 Mrs Catherlne Rustomji LLB (Europe). LPC treslgne(114 Oci 20211 Mr Bobby Ndawula Bsc (Honsl, FCA Ms Liz Richards BA IHonsl. ACA hAs Rosemary Cook CBE. HonDLitL Msc, PGDip. RGN. FQNI.FRSA Dr S￿art Gdffiths BSC. PhD Direct￿ of Research and Servlces Mr Chris Slater MCIPS ITesMJned 02 Feb 3J22) Mrs Clare Field MA (Honsl Oxon Mrfimothywilliams LL8 IHons}. LLM Company SeC￿tsry {retiTed 31 Dec 20201 Or Paul Rice BA (Jolnt Hons). MSC. Pho, FBCS Mr Craig Bonnar MA Hons (Econ) Mr 5am Jenner BA (Honsl LLM TEP (appointed 14 2022) Mr Matt Johnson Bsc (Honsl (appointed 14 Jun 2022) Heathei Jackson MA {Hon51 Oxon (appointed l Oct 2022) Sir Alan Langlands FRSE Hon FMed5ci (appointed 20 Sept 20221 REGISTERED OFFICE SOUCITORS INVESTMENT MANAGERS Jacob Smith House 7 Grove Park Court Harrogate HGI 40P The Chanty engages the most Evelyn Partners appropriate Solicitots for the 45 Gresham 5t given circumstarKe arKI doe5 not London retain a dedicated practice AUDITORS EC2V 7BG REGISTEREO CHARI7 NUMBER 516898 (England and Wal&sl Quilter Cheviot Limited 4th Aoor. The Pinnacle 73 Kir¥J Street anchester RSM UK Audit LLP Central Souaie 29 Wellington 5tsEet Leeds LSI 40L REGISTEREO COMPANY NUMBER 1919823 M24NG BANKER5 Lloyd5 TS8 Bank PIC 617 Park Row Leeds L51 INX Our purpose Yorkshire Cancer Research is dedicated to funding research so that you and those you love live longer, healthier lives. Our aim is for at least 2000 more people to survive cancer in Yorkshire every year. To do this. each year we fund £10 million of world-leading research to prevent, diagnose and treat cancer. llllll -4 .k iiiilw'r Our Vision and Values How we help We fund cancer experts and world-leading researchers who pioneer early cancer diagnosis and discover new and better treatments for people with cancer. These life-giving medical breakthroughs lead to the very best chance of recovery for people in Yorkshire. Vision Mission Goal People in Yorkshire are less likely to get cancer arKI le55 likely to die from It than elsewhere in the country Taking actiorb today to have the biggest impact on cancer for people in Yorkshire 2000 fewer cancer deaths a year in Yorkshl Strategic Aims l. Practical. tanglble. research-led actlvlty 2. Taklng action to prevent cancer in Yorkshire 3. Yortshlre people get the earfle5t possible diagnosls 4. Flnd better treatments to improve Su￿1Val In Yothshire Funding research that saves lives in Yorkshire Thanks to the generosity of supporter5. Yorkshire Cancer Research plays a vltal role in helping more people in Yorkshire get access to the very best cancer treatment. Through the programmes we fund. we help attract the best cancer experts to reduce health inequalities and increase standards of care acr055 our region. 1 £11.7 £11.7 millDn to fijnd Fwon*ring research and seNices to prevent. diagnose and cancer. million 130.000 130,000 people are able to take part in research studies fvnded by yo￿shire Cancer Research. Our charity remains the biggest funder of cancer research stuoy places in Yort Stepping out for Yorkshire with the Tour de Walkshire rwleto W thedurirrfJ of May tytaking on a W5￿￿1(￿￿1￿.￿mCtst ICKK) signed PFV￿Cal aThl.t(xJether. £150kto fund lrf&sarir¥J T￿rC￿l F¥b0FA4ntscC￿J1d thctse towall ￿N￿.t1￿5#KreobleCcffin￿INtywe￿ unit￿1 by the cau car￿r ￿Y￿kSh￿e. ￿eXerC￿1r4j theyyKvp a&0 hdping to rt4n5 arè acted upon the tharity 15 managed effeclivety: this includes develoFMng and •Jreeing the strateolc directionof thethJlty￿ approval ty the P4)ard. Grant Making Policy Research is atthe heart of all we do. Each research award that is funded must meet the charity s strategic aims to prevent. diagnose and treat cancer for pecple in Yorkshire. The quality and strategic fit of ap￿iCatiOnS is assessed in o￿n competitK)n with the help of th2 Research Advisory Panel. The a55e55rnent proce55 is audited and approved by the As￿CIatIOn of Medical Research Charities. Final apprcwal of fundirvj Is reserved to the Board. Public benefit Our Trustees confsm) that they have referred to the Charity Cornmi5sion's ger￿Tal guidance on pttblic benefit when reviewiThJ our primary activities and objectives aThJ in planning our future strategy and direction. F￿blIC benefit is at the heart of what we do a5 a charity and this is demonstrated in the ¢bfe-giving medical breakthrough made through research funded byyorkshire Cancer Re5eaTch. The roydltie5 we receivefrorn the drugs developed as a result of these breakthroughs go straight back into funding further resewchthat will chaNJe lives in the fvture. Award5 are maje underthe terms of a tiinding written framework including fom)al Award Conditions ar¥J Policies fot Awards. Applicant5 are required to adheTe to best practice standards of research governance and ethks. Other fomial terms deal with the handling of intellectual woperty Ptoduced by the rEsearch and its potential eX￿oitation. to ersure the charity's interests are proterted and thaL where appropriate. a retum on publidy donated furhds is In 2014. Yorkshire Cancer Research funded a first. Lynparza. a dnjg developed In Sheffield. became the world's first licenced PARP inhibitor drug. successfully extending the lives of w0n￿n with a wtsin type of advanced ovarian Can￿r. Since its launc￿ the drug has a150 been lice￿ed for Use for Some breast can￿r5, pancreatic cancers prostate Can￿r$ and trials are on- going to See if it could be effectwe against several other cancers too. In aldition. by shDwiThJ that PARP inhibitots can be made to woik. Lynparza has Regular meetiros are held during the conduct of the Award wlth Award Holder5 to measure progress against agreed key performance indicators and to assess progress against Award impact. 31 Fundraising Standards be effectNe duriry the pandemic. We will continue to evofve OUT risk management as the ongoing effects of the pandemic continue At YoTkshire Cancer Research. we work hard to achieve best practice in fundrai5iryJ. We want our supporters, donors and anyone who comes in contact wtth us to feel they have been tseated with ¥e5peci and considerntion. We subscribe to a) Managlny strateglc charye the Fundraising Regulator and Code of Fundraisirrfj tt 15 of paramLmt irnportance that charitie5 are Practice and activety follow their guidance in clear aljout their purpose atKI stratwi aThJ how parallel with that recornmended ty the Charity theywll manage strateg¢c chaThJe. Without thls Commlsslon for England and Wales. Our lrtome clarity. the￿ could be a lack of adequate planning Geneiatlon Commlttee focuses specificalty on arKI inefficient Use of resources arKI. ultimately. fundraising activty and the Oirector reS￿)nSIble a failure to deliver the required public benefit. for Yorkshire Cancer Research's fundraising ten.yEar plan agree¢J bythe Board In 2015, activity reports to this Committee. We also take and ref￿shed from Septembei 2018. is belng caTe to monitor and address changes in relevant re￿e￿￿￿. particularly in light of the pandemic and regulation that rnay not be 5pectfic to charities its effect on Ca￿er patients in the region and the such as the GDPR legislation. development and progre4 of the implementatlon plan Is being carefulty monttored. This review proce55 may result in further strategic changes. b) Dernonstratlng publk ben•fft The g)al of YoA(shire Carte¥ Research is to Meeting and eX￿ainIng our WO￿ to pK)tential achieve 2000 fewer cancer deaths each year in donor5 is irnportarrt in funding our workto Yorkshire by 2025. The public benefit we seek prevent. diagnose and treat cancer across to deliver is. the￿ore. thè effectiveness of the Yorkshire. To do thhs, we work in partnership with a research and 5ervice5 that are fU￿led to prevenL specialist, market-leading fundraislTYJ organi5atiorL diagnose and treat cancer across yoT￿hlre. We require them to cOrnP￿ with fundraising regulation and to display the hvjhest levels of professionalism when talking with potential supporters. Mystery Shoppers help u5 evaluate the degree to which they achieve this and we will work in collaboration with them rfwe recelve any complaints. Response to risk Working with Third Party Fundraisers This year. we contin￿￿ developiThJ our impact analysis rTK*tel. which ha5 refined our undeTStanding of hrm to reach our gDal. Our priority areas have been selected on the basis of delfverltvJ this significant public benefit and indude clinical tria15. smokin*ce5sation. cancer rehabilitation and earfy diagtK6iS. Risk Management The Research and Semces Team reprirts annualty on the irnpact of the charty arxl provide5 regular The Board and Executi¥e Team regularly reviews upJate5 on the prowof key strategic area5 and the major risks to V4hich Yorkshire Cancer Research the impact KPIs_ Is exposed so that as a charity. we can be satisfied that effective and adequate risk management c) Cornpliance and regulatlon and internal control systems are in pla￿. The Yorkshire ca￿er Res&arch continues to grow uncertainties include risks to IrKome. the ability in ordertofund at least £IOm of Tesearch and to fund long-term expenditure and risks to patient servi05 everyyear until 2025. To comply reputatton. The framework is designed to manage with regulation and to mltsgate risl the stfucture, the ri5k5 to our strategic aim5 arKI has proved to organisation. systems arvj contr(A5 of the charity are regularty rewewed. enwres that the 32 yorkshirecanc•rr•searclLorg.uk Flnancial Review starKlard5 of management and control are always maintsined at the most approprSate level for a tharity of our slle and Importance. Safeguarding Members of the Public We continue to make signrficant progre55 to professionaltse the charity. meeting new demaNIs ft)r improvements in regulations relating to tsx. data Protection. donor and volunteer stewardship. health and safety, risk management and a greater emphasls on good employmerrt practices ar stfengthening our govemance framework We are espeualty careful when engaglng vulnerable pe(*)le and those affected by cantèr. charity has reliewed how w￿ recwuit and appoirrt ern￿oyeeS. To supplement the usual qualrfication arKI reference checks. we request a utminal record (hed( as part of our reuuitment proce￿ For certain roles the chKk can a150 Include inforMa￿n held on the DB5 children'5 and adults. bawred lists. tojether with any information held ty prAice forces. that 15 iea50rk3bly considered to be rdevant tothe applied post. As we have noted through this reporL the environment for our research and services has been impacted by CcwSd-19. OinScal trials regulation. approva15 for new drugs or new treatrnent pathways along with the availabilty ( cutting-edge equipment and appioprsately skllled personnel have all affected the abllity of the charity to delNer oui furKled projramrnes. Subsidiaries Wo(xJs Bacon Factory ￿rnIted. a cornpany registereil in EnglaThl and Wales (Company number 003479041. is a Whol￿-0￿ned subsidiary of Yorkshire Can￿1 Research atyj wa5 left to the charity as part of a legacy. The principal activity of the company is the letting of tts properties. There wa5 no trade in theyear and Wocmts Bacon Factory mited was on 6 July 2021. Reserves policy The charity ha5 revtewed its Reserves Poliryand agreed to continue to invest in research over and above net income levels by drawing down from tts reserve5. The charity has decided to have general resetves reflect the expected level of opeiational expenditure and designated fursds represent Research Awards approved but not yet incurred as ell as anticipated f￿Ure Research Awards. Y.C.R. PromotK)ns ￿mIted {Company number 2618142) and Y.CR_ Soentific Developments mited (comp￿ t)Jmber 4194001). cornpanies registered in England arvj Wales and whdly-owned byyorkshtre cAr￿T Researth. were dormant during the year_ The policy is for the level of general reserves to reflect 18 months of future anticipated operatiry cost5 established at £9.9m. General reserves at 31 March 2022 were £11.4 mill¥)n and are therefore In Ilne wlth the policy. Structure and governance We said gcodtye tocatherine Rtjstomji who served a total of 6 years antj Chrls Slater. who had served 3 years as Trustees and have seen the Charitythrougha ￿rIOd ofenormous thang& Complaints. compliments and feedback are an Our ￿artfelt thanks go to CatherSne and Chrls im￿rtant SWTce of information on our ¥￿k for unsbyerving dedscation to the Charity with our impacts on our supp)rters arKI members of the best Wi5he5 for the future. We are delighted to public. providing us with insight and lessonsfor welcome Sam Jenrer and Matt Johnson as new future artwity. In the year to 31 March 2022. one Trustee5. who bjth joined the Board in June 2022. person rnade a complaint to the charitythroughour Their experien￿ will be a valuable addition to the complaints process. The charity responded aThY the Board. complaint was reS0￿ed. We takeall feedbackvery seriously and act upon tt wherever possible. Complaints 33 Trustee recruitment. appointment. induction and training They are ojrrenty. The recruitment pr￿e$S for Trustees 15 cariie(l oui by the Remuneration and Nominations Committee and new Trustees are appointed by the Board All Trustees give freely of their tlme and receNed rK) remuneration in the year. Details of Trustee expenses and relevant third PartYtrar￿act1OTrS are disclosed in note 7 to the financial statements. Trustees ale required to disclose and reyister any relevant Interests arxl the charity uses appropriate protedure5 to a55e55 and deterrnl￿ the proper course of action where a conflict of intwests arlses or may be percelved to arise. New Trustees are selected to fill arhy specific skills gap5 identified. Prospective TIu5tee5 are given a comprehensive overview of the charity's actiwties so that they fLtlly understsnd the contribution they are expected to rnake before they commit to becoming a Trustee. They are gwen guittan on the structure and governan￿ of the Charity. meet with the Chief Executive and are appointed to a Board Committee. New Trustees re￿Ne an inductlon pack of key documents. Induding contract of commitment, ahead of their first meeting and are required to work through these documents with the Cornpany Secretary. Any Immediate trainlng needs are Identified and incorporated within our Trustee development programme. Remuneration Policy charity has a responsibility to ensure remuneration Is appropriate and affordable an(5 jU5ttfiable use of charitable fund& The objectives of our Rernuneration Policy are t ' rward ￿ ￿My)￿baSe￿ ￿ thefrskllls. perfomwnce. contritrArtfiDn cotrrfnltmenttothe char5ty Trustee Delegation The Trustee5 are perrnitted to delegate their pryNers to Committees, which repoft regularty to the Board. These Committees may Include Trustee5. member5 of the Directorate and other senior managers, and independent special adviser5 from outside the charity. Each of these Committee5 is non-executive and has no executwe powers other than those granted in their r*pective terms of reference approved by the Trustees. enable recwuitmEnL retelltion and mDtivationof Iwjh ￿li￿e *npbj￿e5 in aH areasof activity erFjvEt￿ PrOpETw￿ effecti￿ u5eof our resou￿5 ythin sensible, affordabtelimits based on the financlal h￿th￿ thestrateglc thmsofthetharity falr eq￿ta￿le In setthig and marwglng paylevds soasto [￿de a rdk8Lle at¥J gJStalnaL4efr￿￿e￿Qrk comFtywith al relevantiewL4tionsand emplcsyment g￿￿tIL￿ e5peciilly in reL4tlon tostatutoryobligatlons. 34 yorkshlre£ancerresearch.ory.uk Flnancial Revlew malntaln a competltive POSitp)n In theextem emF4oyment market ty ptyr4at or abo* then level for conparab* posts Snthe ¥Cknntarysect￿. In preparing these financial staternents. the trustees are requlred t sew su6tstrJexcowtlngpcMes ￿dthen appty them CO￿￿$¢en￿Y Remuneration Is revlewed on an anThJal basis and agreed by the Board of Trusiee5. When setting pay levels. the charity gNe5 cortsideration to extemal benchmark ccfflparators. change5 in the n3th￿al and regional average pay movements, affordability and other Internal and extwnal pressures Ind￿j0￿j recrultment and retention. the rrnthoI5and ryincple5 inthe Charitle5 esUwAte5that are rea50n8ble and prudent prepare therIn￿clastateMents ort the 90irtg concem basts Is Inar4)rq)rfateto pregjme that the ch¥ttatle conwyv4111 contlnue Inoperauon. Management The Tnjstees have delegate(I responslbS11ty for the day-to-day management of the charity to the Chief Execuibve who has the foilowirg respot￿lb1llties'. 4 5trategic- towovyje inwt and d)8lktye tothe devebpment ofthe chariiy51ory.term traTr￿at￿Jnof that Strategy 1nto0petatK￿￿ Flarts aJwatarytrnethefnaThial FL￿rtthOfthe ¢tsitthComtkyw￿g0Up￿ enableth￿t0 CLYnwi￿￿tKffi.TWareaL￿ore5Pl￿6l￿efL￿ leadership and delivery-to den¥erthe 5trate￿and operational plans and managethe chariiy ￿thin the ddegated authoritiesand accountabA1tyframe4￿xkS down tythe Auditors Board sUP￿-t0 Implement Bo3rddeosw)rts and ertsure they receive the Information èlictthty asa&litDr5rffi IS March 2022 fdky•r0afom￿teTrYerprC(e$S&jIT￿￿* apwovaL Statement of the Board of Trustees. Responsibilities The trustees. who are a150 director5 of Yorkshire Cancer Research for the purpose of company law. are responsible for preparing the tru5tees' report and the financlal statements In accordan￿ with applicable law and United Kingdom Accounti Standards Iunited Kingdom Generally Accepted Accounting Practice). Company Law requires the trustees to prepare financial statements for each financial year which gwe a true and fair view of the state of affairs of the charitable company and the and of the IncomiThJ resources and application of resources Including the income an(5 expenditure. of the charitsble group for thatyear. 35 Independent Auditors Report Yorkshire Cancer Reseaich 36 yorksh1recancerreseu￿1L0ry.￿k Independent Auditort Report Independent auditor's report to the members of Yorkshire Cancer Research Opinion Conclusions relating to going concern h85 bEen appl*d in thsreF#Yt g￿e a twe and falrvknof the stste chafftab compan￿$ affairs asat 31 M¥ch 2022 8ThJol its IrKomlng resourcesand appl*atson of rex￿r[e￿ Indudiny its IncoN* and expentfftwe.fE¥rthe yearthen ervJe4' Other Information . have been properfyprepared in ￿(1)rd￿Ke￿rth Unft•J a¥thtcrt reFt¥tthErwrL ThEbU5ts￿￿eI￿5PL¥G￿IEfL¥thP have been prerAred [r•accordan￿￿ih the requlrements of the CoryarOesAci 2CIJ6. Basis for opinion requirementsthatare relWarttrJtxra*frtof￿rIWJ state￿￿rrts intheUKincknfirotheFRCsEthKaStaTh P￿￿￿￿¥ba*s￿LUr0PXnILyK Opinions on other matters prescribed by the Companies Act 2006 the inforrnation given inthe Tn￿25, Repxt.whKh Indude5the Direcior5' ReFy)rt ¥nJ theStrategK Report *¢oJrtitvJurknthetnJ5tee5alhu rrtendto&yid*ethe prepared for the wrpD5es of axNparry law. foTthe rinancial yearfcr%¥hiththe firArKi* 5taternents are prepared iscon5i5tent y￿th the financlal statemen and the Director5. Report ard thestrategic Re[￿ InckKled Svtihin theTrusiees' Report ha%* been prepired accardance ￿thap￿rab￿ legd req￿reMent& Auditor s responsibilities for the audit of the financial statements Matters on which we are required to report by exception Incbded wrthintr*Tnth'F&rKrt The extent to which the audit was considered capable of detecting irregularities. including fraud adequate accountiThJreLOrdsh￿e noi tr•nkepL or return5 adeqvatefor ourau(fit not been recefved frun branche5 ntrtv1￿tsrf or the financial statementsarÈ Inagreeff*ntwilh the accountlng records and roknrn& or bylaw are not madtr. or ' we have not re£eNed all the Irrfornkn arKI £%FAanatKthswereqwrefgrLWTau Responsibilities of trustees AseWir& mrefiAtyIn￿ Stater￿t0fTnStees. ¢f£oryanylawl¥e resFWJrtsb￿￿theF¥￿￿*K￿L*th￿ 38 yorkshlrecancerr*search.ory.uk Independent Audltorfs Report Use of our report (StirtrwiahlfurK)oth￿￿￿￿yY￿￿.TQlfr*fUjestextent 20110122 Consolidated Financial Statements Yorkshire Cancer .Resea(cli 40 yorkshlrecortcerreséortlLorg.uk Consolidated Financial ststements FINANCIAL STATEMENTS Charity Statement of Financial Activities (Incorporating an Income and Expenditure Account) for the year ended 31 March 2022 Totsi TotAI L75i9)2 ZJ61944 1,386J98 17S1653 1826.392 749249 15.294.430 Total IrKomlng resowces IS.7S0￿6 10.080.695 25AX.S 20.288.SOS ExwditurÈon 1709.C69 ILZIJIZ EwditurÈonthattsNeaÈtr 2Artingperfod CashaThl IU.a17A87) 5.909J65 2&JOgA52 U2(M) Cash cashe4UNalentsatX Ma¥ch2022 28.109.452 aw9.452 I8.2￿A8n ,wi,g Total 28.109A52 (8,207.4871 19,901,965 FINANCIAL STATEMENTS Notes to the financial statements Accountlng polldes Fund 4Kcountlng Charlty Informatlon re￿5t￿redaS8￿￿rttyth p￿￿1paI pkcE 01bJ￿ne$SI$j•jJtssrth1bJ￿. 7&ThEPatkCtsrt Hawat4NorthYrrfksfvir¥, E￿ar￿, DPerat￿nSartSetojI In￿￿T￿Stee5ty BaslsotproparatloTh PractSc•applic*lit0c￿￿Ii05Wtp￿rirOknfin￿o￿51•t4n Inar¢tydancewtthlfv Fknanc￿￿ Repu￿1c0f freland(FR5 I￿)lettEr1Th￿l ￿u￿Y2019j-(cl￿1t￿5 Incombng re50urce5 UKandRewtrAlcOflre￿r￿1FRSIlj2)•*ltr*cry￿kkZ StLY1￿1 w5tuftr￿5￿tbnv*UÈU￿es$lth￿￿l5t51èts￿l￿lhe Epared kn PoLrfStedkngastNsK%v*oJttW0fiJ*wwIWy DonatSons arnl grnnts CarKer Rese¥th)tw beend4sok*d¢knrfrytreyw.ltsre Yorkshlre Cancer Research Status YarksNrÈ CanrerRi5Earth Royalties 1kn5tEdto£l PErrneThkn. Golnytoncern ThErn￿te¢ShWE WE￿e￿¢d￿* forÈcasiXiivkyforai￿a5t 12Montr&frAkiwhwarv￿￿th f￿￿£1* 5tatemonts. In thE1￿￿t￿l ie5E[VElwpts*t￿Tr￿wvVed IniÈrEsiand dlvlderK15 theChaiStyhb5ade4uate rp￿￿￿(e510rOm￿nknlYrknnf0rlhe Resewth•sB tE*teredOwty15rrf>tliBNetOt￿Bti￿￿OThth of èccounbry In y*parln9thOfinanc￿1SLlt0mont￿ ThÈTIu51eosO) n￿t￿nSIder￿ere1Vbe￿ny￿￿tErItiI￿n[Eri￿uknUb￿tthE*￿l[1￿S abll5tytocoTht￿el5a￿rQc￿ Lthsewl rtl*lW(VIy IAolorvElide5 Crltlol accounlSngludyÈrntnts AX￿ asset Inve5tw*Trts ¢Jet¥th￿l￿￿th￿0￿￿a￿K￿jTts01￿55Etsa￿J1￿b1rt￿5b expenthure Imiestme#ts- quoted IrwE5tmpnt5are5tstedBt 1fthetEh￿ybPEnwP1￿￿KalOt50ftsrOJ￿￿TrtIn e*oth¥e rrAthiierFWtyu•Jit fdtyrwahdewtyxtdiecv￿ab1lty. ThEr• 45 (Note5 contlnuqd) Accountlr¥J pollde5 (cryrtlnued) bEmEt. In5LV￿￿t￿￿rKEE.t￿WyI￿sr￿bEEnr￿QTr￿d￿1 Determlnlng re51dual valuesand useful econ0n￿C Ilves yea￿end￿￿[1￿￿ded￿tNnd￿btr￿.0UÉto1he roiweots(wrf of property. plarrt.andequlprn8nt the 1egadesfKE￿E.thE￿L5 jL¥wnentappr￿￿tDth&Vl￿￿￿ K•y sources of estim•llon uncertalnty theperi¢d knwl4¢htr*esini*e$fe%i*d.if Iheth5bJnotlKtsrx* thBtperiDd,orlntr*perbJ¢*theIe￿￿kn1¥ffid￿j1lT￿r￿m1ts riEtennlnlngthe Valua￿on01 legacydebior5 ofe5t1mati0n￿1K￿taM￿.thILh￿￿51￿r0fic￿￿tr￿olu￿ry tEWWEdtobey￿tythRE5trtCtll re￿￿￿e¥hE￿￿Of1￿e kgary. Incomefrom donatklrffj and grnnts T¢* 9E4I314 gf4n4 995 95267 Reta 33i74S antsrecelved 41QfM2 105 $475Z Othe1&maUr￿ L752.902 4UO.042 2.161944 1,386,198 Income from le9ades Total ToiAI IndI￿du* gw9-le￿5 I?￿6￿3 26392 3.7S]￿S] 17¥A.653 1826.292 46 yorkshire¢oncerresearch.org.uk Consolidated Financial ststements IbW•Stment 5ncom• t6￿￿nd$a￿￿1￿terestC4TrIrA%fffl ?81￿86 Eyndlturè on fundraTs]rwJ Totsi zo IWwity4rvJfurfraisroJ 539. 539,701 IJ34.032 U34M32 LIYJ2,131 19U31 6516 15,767 47,736 47,736 751>33 75P33 4S 461 61M2 97.552 98.J92 2337 I706.7a2 I709.rA9 3.735 1117.577 2.12L312 47 (NotthIft1ftTh)Ie 16. £2•￿216505￿theBJlWstrQefJ￿désI￿5￿*ed￿1￿Eta1￿rYjtQl& 48 yorkshire¢an¢erre5Earch.org.uk Consolidated Financial ststements Charliable acllvlUe5 (contlwed) 30 BtaifrydCCG (27 41688 Vniwetytyof￿l L¥l.938 774.354 1,281,767 VniwetgtyofLEsts 363J84 146J9,$00 iÈÉdgGtyCINwl 4%293 49ffl2 utweTrtyCo￿egp LO￿0￿ 29.1 I,SS7,517 UnfversiiyofSheffi* 3,545 3￿￿.759 Sheffiekl HallamUnh*r*ty 43NSS awteDistrfCtFtyJTrJa￿OnTn￿l (4Z171 44JOS un￿*r￿ty0l￿Ol￿ S26350 7W.g Ilorthjmbrfa Unhw*ty 8S9 4￿2.211 9Jbtotsi 4504￿1 L4W335 Z6.974.395 UDNersityofSheffield EThSMrom Fundret 3&1%9 5QD5n SupwtC051515* page50) 40.512 Totsl 5.867.586 s￿28.240 26.974,395 49 (14•tes ￿￿*1￿￿•￿) Charltable actmtjes {contFNed) SupportC05ts- charItabl*aC￿vlll*5 Staff tt IW5.913 I,OZ7,748 wage5aT￿saL￿rl￿s 6P37 37 31 sètskntycasts 44.923 5.195 4.959 L2galaThl prOf￿5￿y￿1S &783 L494.950 1*72.280 Emplwes To Yo Wagesand salaries I￿.[ 1.844.175 ls*cutity£D5ts 3J5355 175N17 )856 114,144 Z.143A36 £YOml - flOO.OOQ £80.(M)l -E90.000 £10￿01 .f&).e J.QOL .£70M S¢i¥kes.OirectDr ThE tu￿*￿￿￿ebe[￿tsN￿dM￿the(Q5lufEff￿￿yeIS Nknn I￿Tan&Co￿t￿I￿QnSDtt￿EEXEoJI1v¢tCw￿wE￿ É45895FU021.£487.5491. bohilfofVorkthlreCaKer R￿urCh￿rirytr*￿ar￿2D2I-£N 50 york5hirecancerresearch.ory.uk Consolidated Financial ststements NetIn￿rnIng resources forthe&*ar are Stat￿ after charyl Totsl Total Al￿{t Fep5 23,035 54.894 Opeiatirgkoe rent pabJ- 9&712 g. Tanyiblé flxed assets operty fijmkne & OIApri13)21 3X*A52 4396n d￿Orts 249 137.691 31 Z022 eprEclgUryi Oi April 3Q771 0wrgetlwv￿1Wr 71330 3IMwth2ffj2 78AX Netbookvalue 3L037 2265 at3lMa￿hI0Z? 31 K*arch2ts2k 4.ia 176.900 51 10. Flxed asset Irp4estments Total artetY*￿at IW12011 7fi￿595 2&172 ditbr 7J54,ODF 1&05L782 25JQ5.789 23ffi7597 L*p05it3 Q2W16) I16￿?￿j 4.75B Markelvalue at31 Flarch2022 35.096.158 21.692.3n SF.7a8.535 Urtrea1￿d 2A¥J￿ 4.758fj48 Total Aalis7A45 125S.353 35m6.157 32.752.622 At31 Marth2022nDQIE1￿1n9eXrEed￿d 5%0fIhe￿￿of￿*VK￿fdkn{3l IA¥th 1021no(rf*Wr¥Jexe•l&JSY4 Trk1rwestmentp¢rtl¢lo*s•JMtste￿d￿¢)Jlt¢T o￿vAL4r￿tvj É¥etynPwtnw 52 york5hirecancerre5eartlLorg.uk Con501idated Financial statements 14582 YLR. p￿￿￿>t￿m￿UThYt8J-C0sl*3I March yLR.knti￿ Ltirited-costat31 March3)22 202 14,784 Iiiwrrtofit5B55ets. ￿￿bI￿O5￿￿1￿nds8l3I Marth 2022￿1￿￿11(3)2l. £7.>J7XThEcEYnp￿UtstL￿￿%orthEYearto3l K4¥th2021 harfty TLrt•l IAwla)ZE 55),057 217,321 311AychlOZI 777.378 knpalrlnwrt 31 March2021 Netbook¥alueat31 I1￿Ch2O22 777.378 777,378 31 MarthZIFZI SY).OS7 Cl￿$ Blotethnologyumlted a)21. BgJldOFwrturwtk5PLCwa59Jb5EqupntyiewfflEdOEth￿Ot￿tr￿N￿PLc•dyoS￿*￿tth￿toV% DfthpLDrthn5tock Exchangeon 14 klryJ)21 AsèresultOltr￿SthQ￿W1tt￿￿ was￿￿r5Ed￿n1ht I4¥th￿21 fin￿￿￿$￿t*fflentsandtr￿ irNtstmtot tsvalued ktthpaThKjUntorpJn*typh￿ ar￿ ￿ 1142160fthe￿￿dsNwe¢ép￿#. Itsw¥wdx1Mtyi4thEd￿Qfb￿￿0yk￿J￿ents 53 (Notest¢>ntrrtuqd) In￿￿mIn￿￿e*lthInlThS Tradedebtars 676?53 4J,261 6%7n L598MY8 5A44AI 4321793 8.8ty)A14 6.406.359 13. Gish at bank and In hawwj Cash atbank and In hand 19.901.965 28.W9A5Z Creditojx am￿ntsfa1lIng duewlthln oneyear 314272 TaXètknftar￿ 49.381 ,140 3￿j61 (438A 3AW54 6.614A2B 54 yorkshlrecancorresearclLorg.uk Consolidated Financlal ststements 1% OperatlbVJ Itase commltrnents Charfty IO&YJ5 EMpiringtwotofr*eJw 195,325 215.773 150.160 i& stst•m•nt of fund5 Totsl Jnd5 Fur ToLh* AtiAwP 8231A￿ 4IW.318 I445.￿ s￿1￿27 21LJA5 69I1W40 3.191W 61Q042 25TrL52L 2041 111654177) Net IJ95A55 L837,5LI UWi.349) dÉsv¥*tsdduritKJthe At 31 ma￿h1o?2 .665.111 Sl.963,246 Z.Z3&769 IOA48MI 5.794.657 s5?￿23 84.051207 55 (Not*s continu•d) 16. Ststementof funds(eontlnued) ofH k%y*Lir Atiwii 137,315 ￿.921 507,U96 759 Ewuiture (ZJ5UWI 11811651 WJI8) IF7422BI 13MYJ (U8) iow7.n71 Net Irrt*stmont SJ8&23) U5.6VJAMI 1*624740 .FuThts dÈ5bJn3ted OJrfrrfJthe At 31 Maich 20a ¢237,452 47.941.318 I￿65￿+ 1444769 5JJ37.527 2595Xdg ZU.185 69￿6. ItnEcledindp￿9natedfu￿ds.T￿s￿￿h￿ththE¢JW1tySStr￿t￿Cc￿lTI¢￿1Spp¥￿¥tlQ￿￿ryeU￿a£t￿its¢￿tsYealnS. tr*llgreemwt. th5$fvr￿ bbEWVJu5Edt05w￿aS&wIeswthaw￿[dtotr￿UrknV*Orleeok TIbtYothsl￿r•c￿nClr R￿￿hSn¢￿￿ Lif*Toth*Funrtat*ie5trKtedfvnd5rd&tiryts> Lynparzartyatyshaie iec*VEdquarLertyttrrfW￿tthe F￿￿￿tr¥￿ttl￿*dtQ•Wrt￿reStbP￿rry irrtestmont a￿t￿nt￿n 56 york5hirecancorresear